Lv3
360 积分 2022-05-24 加入
Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy
5天前
已完结
Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives
5天前
已完结
Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial
8天前
已完结
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
10天前
已完结
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
12天前
已完结
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
23天前
已完结
Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer—Is a New Era Coming?
24天前
已完结
Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer
30天前
已完结
Extensive‐stage small‐cell lung cancer: Current management and future directions
1个月前
已完结
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
1个月前
已完结
皖公网安备34019202002308
